Jason Coloma, Maze Therapeutics CEO
December 3, 2024 09:07 AM EST
Financing
Startups

Af­ter deal about-face and a spin­out, Maze as­sem­bles $115M Se­ries D

Kyle LaHucik

Senior Reporter

Bay Area biotech Maze Ther­a­peu­tics said Tues­day it com­plet­ed a $115 mil­lion Se­ries D, weeks af­ter split­ting off some of its ALS …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

A service from the Financial Times